Trophos will initiate a European Phase II clinical trial in diabetic neuropathic pain, employing its lead compound TRO19622, by the end of 2006. This follows the successful outcome of preclinical studies.
TRO19622 has successfully completed Phase I clinical trials. The medication was well-tolerated, achieved the predicted effective clinical dose, and had an excellent safety profile. Trophos now expects to move forward with a Phase II clinical study in the diabetic neuropathic pain indication by the end of 2006.